ATE61731T1 - Wirksubstanzen enthaltende hydrogelvorrichtungen, worin das konzentrationsprofil der wirksubstanz einen sigmoidalen konzentrationsgradienten zur konstanten freisetzung besitzt, deren herstellung und verwendung. - Google Patents

Wirksubstanzen enthaltende hydrogelvorrichtungen, worin das konzentrationsprofil der wirksubstanz einen sigmoidalen konzentrationsgradienten zur konstanten freisetzung besitzt, deren herstellung und verwendung.

Info

Publication number
ATE61731T1
ATE61731T1 AT85810213T AT85810213T ATE61731T1 AT E61731 T1 ATE61731 T1 AT E61731T1 AT 85810213 T AT85810213 T AT 85810213T AT 85810213 T AT85810213 T AT 85810213T AT E61731 T1 ATE61731 T1 AT E61731T1
Authority
AT
Austria
Prior art keywords
active agent
manufacture
devices containing
constant release
sigmoidal
Prior art date
Application number
AT85810213T
Other languages
English (en)
Inventor
Ping I Dr Lee
Original Assignee
Ciba Geigy Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ciba Geigy Ag filed Critical Ciba Geigy Ag
Application granted granted Critical
Publication of ATE61731T1 publication Critical patent/ATE61731T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Preparation (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Detergent Compositions (AREA)
  • Cosmetics (AREA)
  • Macromonomer-Based Addition Polymer (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
  • Colloid Chemistry (AREA)
  • Medicines Containing Plant Substances (AREA)
AT85810213T 1984-05-10 1985-05-07 Wirksubstanzen enthaltende hydrogelvorrichtungen, worin das konzentrationsprofil der wirksubstanz einen sigmoidalen konzentrationsgradienten zur konstanten freisetzung besitzt, deren herstellung und verwendung. ATE61731T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US06/608,756 US4624848A (en) 1984-05-10 1984-05-10 Active agent containing hydrogel devices wherein the active agent concentration profile contains a sigmoidal concentration gradient for improved constant release, their manufacture and use
EP85810213A EP0164311B1 (de) 1984-05-10 1985-05-07 Wirksubstanzen enthaltende Hydrogelvorrichtungen, worin das Konzentrationsprofil der Wirksubstanz einen sigmoidalen Konzentrationsgradienten zur konstanten Freisetzung besitzt, deren Herstellung und Verwendung

Publications (1)

Publication Number Publication Date
ATE61731T1 true ATE61731T1 (de) 1991-04-15

Family

ID=24437841

Family Applications (1)

Application Number Title Priority Date Filing Date
AT85810213T ATE61731T1 (de) 1984-05-10 1985-05-07 Wirksubstanzen enthaltende hydrogelvorrichtungen, worin das konzentrationsprofil der wirksubstanz einen sigmoidalen konzentrationsgradienten zur konstanten freisetzung besitzt, deren herstellung und verwendung.

Country Status (16)

Country Link
US (1) US4624848A (de)
EP (1) EP0164311B1 (de)
JP (1) JPS619A (de)
AT (1) ATE61731T1 (de)
AU (1) AU583507B2 (de)
CA (1) CA1246447A (de)
DE (1) DE3582193D1 (de)
DK (1) DK205185A (de)
ES (1) ES542948A0 (de)
FI (1) FI851801A7 (de)
GR (1) GR851114B (de)
IL (1) IL75129A (de)
NZ (1) NZ212030A (de)
PH (1) PH24100A (de)
PT (1) PT80416B (de)
ZA (1) ZA853511B (de)

Families Citing this family (136)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4749576A (en) * 1984-05-10 1988-06-07 Ciba-Geigy Corporation Active agent containing hydrogel devices wherein the active agent concentration profile contains a sigmoidal concentration gradient for improved constant release, their manufacture and use
JPS61218517A (ja) * 1985-03-25 1986-09-29 Bio Materiaru Yunibaasu:Kk 経皮吸収製剤
FR2585246A1 (fr) * 1985-07-26 1987-01-30 Cortial Procede d'obtention de formes pharmaceutiques solides a liberation prolongee
US4794002A (en) * 1985-11-01 1988-12-27 Monsanto Company Modified polymeric surfaces and process for preparing same
JPH0643851B2 (ja) * 1986-03-13 1994-06-08 大同メタル工業株式会社 軸受ユニット
US4983400A (en) * 1986-06-16 1991-01-08 Merck & Co., Inc. Controlled release combination of carbidopa/levodopa
US4780236A (en) * 1986-06-20 1988-10-25 Kiwi Brands, Inc. Lavoratory cleansing block containing polyethylene gycol disteatrate, guar gum and sodium chloride
US4743248A (en) * 1986-08-11 1988-05-10 Alza Corporation Dosage form for delivering acid sensitive beneficial agent
GB8620845D0 (en) * 1986-08-28 1986-10-08 Reckitt & Colmann Prod Ltd Treatment of textile surfaces
EP0297650A1 (de) * 1987-06-26 1989-01-04 Duphar International Research B.V Zusammensetzungen mit Freisetzung nullter Ordnung und Verfahren zu ihrer Herstellung
US5219575A (en) * 1987-06-26 1993-06-15 Duphar International Research B.V. Compositions with controlled zero-order delivery rate and method of preparing these compositions
US4910015A (en) * 1987-10-19 1990-03-20 Massachusetts Institute Of Technology Surface-active polysiloxanes and drug releasing materials thereof
GB8801863D0 (en) * 1988-01-28 1988-02-24 Fulmer Yarsley Ltd Pharmaceutical formulations with controlled drug release
US6440457B1 (en) * 1993-05-27 2002-08-27 Alza Corporation Method of administering antidepressant dosage form
DE69603577T2 (de) 1995-02-10 1999-11-25 Medtronic, Inc. Verfahren und vorrichtung zur verabreichung von analgetika
US5945125A (en) * 1995-02-28 1999-08-31 Temple University Controlled release tablet
US20030203036A1 (en) 2000-03-17 2003-10-30 Gordon Marc S. Systems and processes for spray drying hydrophobic drugs with hydrophilic excipients
GB9703673D0 (en) * 1997-02-21 1997-04-09 Bradford Particle Design Ltd Method and apparatus for the formation of particles
US6039968A (en) * 1997-06-24 2000-03-21 Hoechst Marion Roussel Intravaginal drug delivery device
DE19843904A1 (de) * 1998-09-24 2000-03-30 Basf Ag Feste Dosierungsform mit polymerem Bindemittel
DE19843903A1 (de) * 1998-09-24 2000-03-30 Basf Ag Feste Dosierungsform mit copolymerem Bindemittel
US6706283B1 (en) * 1999-02-10 2004-03-16 Pfizer Inc Controlled release by extrusion of solid amorphous dispersions of drugs
US7943162B2 (en) * 1999-10-21 2011-05-17 Alcon, Inc. Drug delivery device
PT1242055E (pt) 1999-12-23 2008-07-02 Pfizer Prod Inc Forma de dosagem de fármaco baseada em hidrogel
US20030086972A1 (en) * 2000-08-09 2003-05-08 Appel Leah E. Hydrogel-driven drug dosage form
GB0027357D0 (en) * 2000-11-09 2000-12-27 Bradford Particle Design Plc Particle formation methods and their products
CN1203814C (zh) 2001-07-23 2005-06-01 爱尔康公司 眼部药物输送装置
ES2271301T3 (es) * 2001-07-23 2007-04-16 Alcon, Inc. Dispositivo de suministro de farmaco oftalmico.
JP4551089B2 (ja) * 2001-10-29 2010-09-22 マサチューセッツ インスティテュート オブ テクノロジー 三次元印刷により製造されたゼロ次放出プロフィール投薬形態のような徐放投薬形態を製造するためのシステム
GB0216562D0 (en) 2002-04-25 2002-08-28 Bradford Particle Design Ltd Particulate materials
US9339459B2 (en) 2003-04-24 2016-05-17 Nektar Therapeutics Particulate materials
GB0310636D0 (en) * 2003-05-08 2003-06-11 Nektar Therapeutics Uk Ltd Particulate materials
KR20060015587A (ko) 2003-05-08 2006-02-17 넥타 쎄라퓨틱스 유케이 리미티드 미립물
JP2007526019A (ja) * 2003-07-10 2007-09-13 アルコン，インコーポレイティド 眼科用薬物送達デバイス
US20060246109A1 (en) * 2005-04-29 2006-11-02 Hossainy Syed F Concentration gradient profiles for control of agent release rates from polymer matrices
US8187639B2 (en) * 2005-09-27 2012-05-29 Tissue Tech, Inc. Amniotic membrane preparations and purified compositions and anti-angiogenesis treatment
CA2999420A1 (en) * 2005-09-27 2007-04-05 Tissuetech, Inc. Amniotic membrane preparations and purified compositions and methods of use
CN101583620B (zh) 2005-11-28 2016-08-17 马里纳斯医药公司 加奈索酮组合物及其制备和使用方法
US8246973B2 (en) 2006-06-21 2012-08-21 Advanced Cardiovascular Systems, Inc. Freeze-thaw method for modifying stent coating
WO2008079440A2 (en) 2006-07-10 2008-07-03 Medipacs, Inc. Super elastic epoxy hydrogel
WO2008021368A2 (en) 2006-08-11 2008-02-21 The Johns Hopkins University Compositions and methods for neuroprotection
EA018573B1 (ru) 2006-09-22 2013-09-30 Фармасайкликс, Инк. Ингибиторы тирозинкиназы брутона
US8263641B2 (en) 2007-09-10 2012-09-11 Calcimedica, Inc. Compounds that modulate intracellular calcium
US9995295B2 (en) 2007-12-03 2018-06-12 Medipacs, Inc. Fluid metering device
EP2321303B1 (de) 2008-08-27 2019-11-27 Calcimedica, Inc. Verbindungen als modulatoren von intrazellulärem calcium
WO2010124296A2 (en) 2009-04-24 2010-10-28 Tissuetech, Inc. Compositions containing hc•ha complex and methods of use thereof
WO2011032011A1 (en) 2009-09-10 2011-03-17 Medipacs, Inc. Low profile actuator and improved method of caregiver controlled administration of therapeutics
US7741330B1 (en) 2009-10-12 2010-06-22 Pharmacyclics, Inc. Pyrazolo-pyrimidine inhibitors of Bruton's tyrosine kinase
US9500186B2 (en) 2010-02-01 2016-11-22 Medipacs, Inc. High surface area polymer actuator with gas mitigating components
EP2558866B1 (de) 2010-04-15 2016-08-17 Tracon Pharmaceuticals, Inc. Potenzierung einer antikrebs-wirkung durch eine kombinationstherapie mit ber-pfad-hemmern
JP2013525448A (ja) 2010-04-27 2013-06-20 カルシメディカ，インク． 細胞内カルシウムを調節する化合物
WO2011139489A2 (en) 2010-04-27 2011-11-10 Calcimedica Inc. Compounds that modulate intracellular calcium
CA3007787C (en) 2010-06-03 2020-03-10 Pharmacyclics Llc The use of inhibitors of bruton's tyrosine kinase (btk)
AU2011293201B2 (en) 2010-08-27 2015-11-05 Calcimedica Inc. Compounds that modulate intracellular calcium
WO2012061556A1 (en) 2010-11-03 2012-05-10 Flugen, Inc. Wearable drug delivery device having spring drive and sliding actuation mechanism
MX350838B (es) 2011-02-11 2017-09-18 Grain Proc Corporation * Composicion de sal.
WO2012149486A1 (en) 2011-04-28 2012-11-01 Tissuetech, Inc. Methods of modulating bone remodeling
ES2822301T3 (es) 2011-06-10 2021-04-30 Tissuetech Inc Métodos de procesamiento de tejidos de soporte fetal
RU2609833C2 (ru) 2011-09-13 2017-02-06 Фармасайкликс Элэлси Лекарственные формы ингибитора гистондиацетилазы в комбинации с бендамутином и их применение
US8377946B1 (en) 2011-12-30 2013-02-19 Pharmacyclics, Inc. Pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine compounds as kinase inhibitors
ES2793148T3 (es) 2012-01-06 2020-11-13 Lundbeck La Jolla Research Center Inc Compuestos de carbamato y métodos para fabricarlos y usarlos
CN104302689A (zh) 2012-03-14 2015-01-21 麦德医像公司 含有过量活性分子的智能聚合物材料
EA201492082A1 (ru) 2012-06-04 2015-03-31 Фармасайкликс, Инк. Кристаллические формы ингибитора тирозинкиназы брутона
KR102236805B1 (ko) 2012-07-11 2021-04-05 티슈테크, 인코포레이티드 Hc-ha/ptx3 복합체를 함유하는 조성물 및 이의 사용 방법
AU2013323206B2 (en) 2012-09-28 2017-07-20 Fred Hutchinson Cancer Center Compounds and methods for preventing, treating and/or protecting against sensory hair cell death
WO2014059333A1 (en) 2012-10-12 2014-04-17 Calcimedica, Inc. Compounds that modulate intracellular calcium
US9611263B2 (en) 2013-10-08 2017-04-04 Calcimedica, Inc. Compounds that modulate intracellular calcium
JP6345786B2 (ja) 2013-12-05 2018-06-20 ファーマサイクリックス エルエルシー ブルトン型チロシンキナーゼの阻害剤
WO2015164213A1 (en) 2014-04-23 2015-10-29 The Research Foundation For The State University Of New York A rapid and efficient bioorthogonal ligation reaction and boron-containing heterocycles useful in conjuction therewith
TW201603818A (zh) 2014-06-03 2016-02-01 組織科技股份有限公司 組成物及方法
US9775978B2 (en) 2014-07-25 2017-10-03 Warsaw Orthopedic, Inc. Drug delivery device and methods having a retaining member
US9764122B2 (en) 2014-07-25 2017-09-19 Warsaw Orthopedic, Inc. Drug delivery device and methods having an occluding member
US9839644B2 (en) 2014-09-09 2017-12-12 ARKAY Therapeutics, LLC Formulations and methods for treatment of metabolic syndrome
US9359316B1 (en) 2014-11-25 2016-06-07 Concentric Analgesics, Inc. Prodrugs of phenolic TRPV1 agonists
US9493482B2 (en) 2015-02-06 2016-11-15 University Of Washington Compounds and methods for preventing or treating sensory hair cell death
US10227333B2 (en) 2015-02-11 2019-03-12 Curtana Pharmaceuticals, Inc. Inhibition of OLIG2 activity
US20160243288A1 (en) 2015-02-23 2016-08-25 Tissuetech, Inc. Apparatuses and methods for treating ophthalmic diseases and disorders
WO2016138479A1 (en) 2015-02-27 2016-09-01 Curtana Pharmaceuticals, Inc. Inhibition of olig2 activity
IL315294A (en) 2015-03-03 2024-10-01 Pharmacyclics Llc Pharmaceutical formulations of bruton's tyrosine kinase inhibitor
MA41828A (fr) 2015-03-27 2018-01-30 Pharmacyclics Llc Co-cristaux d'un inhibiteur de la tyrosine kinase de bruton
MA41827A (fr) 2015-03-27 2018-01-30 Pharmacyclics Llc Formes solvatées d'un inhibiteur de la tyrosine kinase de bruton
CA2984480A1 (en) 2015-05-11 2016-11-17 Abide Therapeutics, Inc. Methods of treating inflammation or neuropathic pain
EP3297645A4 (de) 2015-05-20 2018-12-12 Tissuetech, Inc. Zusammensetzungen und verfahren zur verhinderung der proliferation und des epithelial-mesenchymalen übergangs von epithelzellen
HK1256718A1 (zh) 2015-08-31 2019-10-04 药品循环有限责任公司 用於治疗多发性骨髓瘤的btk抑制剂组合
US10076650B2 (en) 2015-11-23 2018-09-18 Warsaw Orthopedic, Inc. Enhanced stylet for drug depot injector
EP3389695A4 (de) 2015-12-16 2019-10-09 The Walter and Eliza Hall Institute of Medical Research Hemmung von cytokininduziertem sh2-protein in nk-zellen
WO2017125423A1 (en) 2016-01-19 2017-07-27 Janssen Pharmaceutica Nv Formulations/compositions comprising a btk inhibitor
CN114681462A (zh) 2016-01-19 2022-07-01 詹森药业有限公司 包含btk抑制剂的配制品/组合物
TW201733600A (zh) 2016-01-29 2017-10-01 帝聖工業公司 胎兒扶持組織物及使用方法
US10851123B2 (en) 2016-02-23 2020-12-01 Concentric Analgesics, Inc. Prodrugs of phenolic TRPV1 agonists
CA3054674A1 (en) 2016-04-04 2017-12-10 Sinopia Biosciences, Inc. Treating extrapyramidal syndrome using trapidil
EP3463576A4 (de) 2016-05-25 2020-01-15 Concentric Analgesics, Inc. Prodrugs von phenolischen trpv1-agonisten in kombination mit lokalanästhetika und vasokonstriktoren für verbesserte lokalanästhesie
WO2017205762A1 (en) 2016-05-27 2017-11-30 Pharmacyclics Llc Inhibitors of interleukin-1 receptor-associated kinase
WO2017205769A1 (en) 2016-05-27 2017-11-30 Pharmacyclics Llc Inhibitors of interleukin-1 receptor-associated kinase
WO2017205766A1 (en) 2016-05-27 2017-11-30 Pharmacyclics Llc Inhibitors of interleukin-1 receptor-associated kinase
US10549081B2 (en) 2016-06-23 2020-02-04 Warsaw Orthopedic, Inc. Drug delivery device and methods having a retaining member
US11090702B2 (en) * 2016-06-28 2021-08-17 Trustees Of Tufts College Compositions and methods for delivery of active agents
AU2017298142B2 (en) 2016-07-18 2021-11-11 Arthrosi Therapeutics, Inc. Compounds, compositions and methods for treating or preventing a symptom associated with gout or hyperuricemia
US11242323B2 (en) 2016-08-26 2022-02-08 Curtana Pharmaceuticals, Inc. Inhibition of OLIG2 activity
US10434261B2 (en) 2016-11-08 2019-10-08 Warsaw Orthopedic, Inc. Drug pellet delivery system and method
EP3541807B1 (de) 2016-11-16 2021-09-29 H. Lundbeck A/S Eine kristalline form eines magl-inhibitors
AU2017361254B2 (en) 2016-11-16 2021-09-23 H. Lundbeck A/S. Pharmaceutical formulations
JP7397487B2 (ja) 2017-09-01 2023-12-13 ユニヴァーシティ オブ ワシントン 感覚有毛細胞死を予防または処置するための化合物の結晶形態
US11685722B2 (en) 2018-02-28 2023-06-27 Curtana Pharmaceuticals, Inc. Inhibition of Olig2 activity
CA3107433A1 (en) 2018-07-27 2020-01-30 Concentric Analgesics, Inc. Pegylated prodrugs of phenolic trpv1 agonists
BR112021010708A2 (pt) 2018-12-06 2021-08-24 Arthrosi Therapeutics, Inc. Formas cristalinas de um composto para tratar ou prevenir gota ou hiperuricemia
KR20210102933A (ko) 2018-12-06 2021-08-20 아쓰로시 테라퓨틱스, 인크. 통풍 또는 고뇨산혈증의 치료 또는 예방 방법
EA202191852A1 (ru) 2018-12-31 2022-03-18 Биомеа Фьюжн, Ллс Необратимые ингибиторы взаимодействия менин-mll
SG11202109899VA (en) 2019-03-15 2021-10-28 Unicycive Therapeutics Inc Nicorandil derivatives
CN121550230A (zh) 2020-03-26 2026-02-24 希诺皮亚生物科学公司 同位素标记的曲匹地尔衍生物
CN115427403A (zh) 2020-04-21 2022-12-02 H.隆德贝克有限公司 单酰基甘油脂肪酶抑制剂的合成
EP4149934A4 (de) 2020-05-11 2024-05-15 Cleave Therapeutics, Inc. Kristalline formen und formulierungen eines vcp/p97-inhibitors
WO2022133064A1 (en) 2020-12-16 2022-06-23 Biomea Fusion, Inc. Fused pyrimidine compounds as inhibitors of menin-mll interaction
WO2022150525A1 (en) 2021-01-06 2022-07-14 Awakn Life Sciences Mdma in the treatment of alcohol use disorder
EP4337316A1 (de) 2021-05-11 2024-03-20 Awakn Ls Europe Holdings Limited Therapeutische aminoindanverbindungen und zusammensetzungen
IL309073A (en) 2021-06-03 2024-02-01 Arcadia Medicine Inc Enantiomeric entactogen compounds and methods of their use.
AU2022325861A1 (en) 2021-08-11 2024-02-29 Biomea Fusion, Inc. Covalent inhibitors of menin-mll interaction for diabetes mellitus
IL310717A (en) 2021-08-20 2024-04-01 Biomea Fusion Inc Crystalline form of N-[4-[4-(4-morpholinyl)-7H-PYRROLO[2,3-D]PYRIMIDIN-6-YL]PHENYL]-4-[[3(R)-[(1-OXO ] -2-PROPEN-1-YL)AMINO]-1-PIPERIDINYL]METHYL]-2-PYRIDINECARBOXAMIDE, IRREVERSIBLE MENIN-MLL INHIBITOR FOR CANCER TREATMENT
WO2023028092A2 (en) 2021-08-23 2023-03-02 Alexander Shulgin Research Institute Fluorinated empathogens
US12043605B2 (en) 2021-08-23 2024-07-23 Alexander Shulgin Research Institute, Inc. Deuterated empathogens
WO2023027966A1 (en) 2021-08-24 2023-03-02 Biomea Fusion, Inc. Pyrazine compounds as irreversible inhibitors of flt3
WO2023034184A1 (en) 2021-08-31 2023-03-09 Cerespir Incorporated Co-crystals
EP4396162A4 (de) 2021-09-03 2025-11-12 Alexander Shulgin Res Institute Inc Asymmetrische allyltryptamine
US20240409558A1 (en) 2021-09-13 2024-12-12 Biomea Fusion, Inc. Irreversible inhibitors of kras
IL311647A (en) 2021-09-25 2024-05-01 Alexander Shulgin Res Institute Inc Converted phenylalkylamines
US20250066386A1 (en) 2021-11-09 2025-02-27 Biomea Fusion, Inc. Inhibitors of kras
JP2025502748A (ja) 2021-12-30 2025-01-28 バイオメア フュージョン，インコーポレイテッド Ｆｌｔ３の阻害剤としてのピラジン化合物
WO2023139163A1 (en) 2022-01-19 2023-07-27 Awakn Ls Europe Holdings Limited 1,3-benzodioxole esters and their therapeutic use
CA3244485A1 (en) 2022-02-16 2023-08-24 Awakn Ls Europe Holdings Limited BRIDGED CYCLIC COMPOUNDS AND THEIR THERAPEUTIC USE AS CNS AGENTS
WO2023235618A1 (en) 2022-06-03 2023-12-07 Biomea Fusion, Inc. Fused pyrimidine compounds as inhibitors of menin
EP4551573A1 (de) 2022-07-06 2025-05-14 Oppilan Pharma Ltd. Kristalline formen eines s1p-rezeptormodulators
TW202430528A (zh) 2023-01-18 2024-08-01 美商拜歐米富士恩股份有限公司 Ｎ－［４－［４－（４－嗎啉基）－７ｈ－吡咯並［２，３－ｄ］嘧啶－６－基］苯基］－４－［［３（ｒ）－［（１－氧代－２－丙烯－１－基）氨基］－１－哌啶基］甲基］－２－吡啶甲醯胺的結晶形式作為ｍｅｎｉｎ－ｍｌｌ相互作用的共價抑制劑
US20250002458A1 (en) 2023-05-24 2025-01-02 Unicycive Therapeutics Inc. Salt forms of nicorandil derivative
WO2024249950A1 (en) 2023-06-02 2024-12-05 Biomea Fusion, Inc. Fused pyrimidine compounds as inhibitors of menin
US20250145571A1 (en) 2023-09-26 2025-05-08 Unicycive Therapeutics, Inc. Amino acid prodrugs of nicorandil
WO2025194102A1 (en) 2024-03-15 2025-09-18 Unicycive Therapeutics, Inc. Pyridine modified nicorandil derivatives

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH468192A (de) * 1964-06-19 1969-02-15 Ciba Geigy Verfahren zur Herstellung von Arzneimitteln in Perlenform
IT1050353B (it) * 1966-01-06 1981-03-10 Ceskoslovenska Akademie Ved Supporti per sostanze biologigamente attive
US3660563A (en) * 1966-07-26 1972-05-02 Nat Patent Dev Corp Water soluble entrapping of a drug
US3660071A (en) * 1966-07-26 1972-05-02 Nat Patent Dev Corp Water soluble entrapping of a pesticide
US3577512A (en) * 1968-10-11 1971-05-04 Nat Patent Dev Corp Sustained release tablets
US3576760A (en) * 1969-06-13 1971-04-27 Nat Patent Dev Corp Water soluble entrapping
DE2031871C3 (de) * 1970-06-27 1974-06-27 Roehm Gmbh, 6100 Darmstadt Überzugsmasse für Arzneiformen
GB1394990A (en) * 1971-08-12 1975-05-21 Hydrophilics Int Inc Copolymers and compositions containing copolymers
US4056496A (en) * 1972-10-02 1977-11-01 Corneal Sciences, Inc. Hydrogels and articles made therefrom
US4070348A (en) * 1973-07-25 1978-01-24 Rohm Gmbh Water-swellable, bead copolymer
US4178361A (en) * 1973-09-10 1979-12-11 Union Corporation Sustained release pharmaceutical composition
US4007258A (en) * 1973-09-10 1977-02-08 Union Corporation Sustained release pesticidal composition
CH621561A5 (en) * 1974-01-14 1981-02-13 Ceskoslovenska Akademie Ved Process for producing a bromocyan-activated, hydrophilic, polymeric carrier for biologically active compounds in dried form
US3923939A (en) * 1974-06-07 1975-12-02 Alza Corp Process for improving release kinetics of a monolithic drug delivery device
US4177056A (en) * 1974-06-27 1979-12-04 Ciba-Geigy Corporation Water-insoluble hydrophilic copolymers used as carriers for medicaments and pesticides
US4248855A (en) * 1976-08-27 1981-02-03 Hydrophilics International, Inc. Pharmaceutical base salts
US4164560A (en) * 1977-01-05 1979-08-14 Folkman Moses J Systems for the controlled release of macromolecules
US4304591A (en) * 1978-01-25 1981-12-08 Ciba-Geigy Corporation Water-insoluble hydrophilic copolymers used as carriers for medicaments and pesticides
CA1125698A (en) * 1978-03-09 1982-06-15 Masaru Yoshida Process for preparing a polymer composition
US4267295A (en) * 1979-02-09 1981-05-12 Syntex (U.S.A.) Inc. Polymeric compositions and hydrogels formed therefrom
US4357312A (en) * 1981-07-16 1982-11-02 The Children's Hospital Medical Center Method of making prolonged release body
IL70071A (en) * 1982-11-01 1987-12-31 Merrell Dow Pharma Multilayered sustained release pharmaceutical tablets having non-uniform distribution of active ingredient
US4564364A (en) * 1983-05-26 1986-01-14 Alza Corporation Active agent dispenser
GB8319766D0 (en) * 1983-07-22 1983-08-24 Graham N B Controlled release device

Also Published As

Publication number Publication date
ZA853511B (en) 1985-12-24
FI851801L (fi) 1985-11-11
DE3582193D1 (de) 1991-04-25
JPS619A (ja) 1986-01-06
FI851801A7 (fi) 1985-11-11
CA1246447A (en) 1988-12-13
EP0164311B1 (de) 1991-03-20
ES8603273A1 (es) 1986-01-01
GR851114B (de) 1985-11-25
FI851801A0 (fi) 1985-05-08
DK205185D0 (da) 1985-05-09
EP0164311A2 (de) 1985-12-11
PT80416B (en) 1987-04-16
NZ212030A (en) 1988-01-08
PT80416A (en) 1985-06-01
IL75129A (en) 1989-08-15
IL75129A0 (en) 1985-09-29
PH24100A (en) 1990-03-05
AU583507B2 (en) 1989-05-04
AU4221685A (en) 1985-11-14
DK205185A (da) 1985-11-11
US4624848A (en) 1986-11-25
ES542948A0 (es) 1986-01-01
EP0164311A3 (en) 1987-06-03

Similar Documents

Publication Publication Date Title
ATE61731T1 (de) Wirksubstanzen enthaltende hydrogelvorrichtungen, worin das konzentrationsprofil der wirksubstanz einen sigmoidalen konzentrationsgradienten zur konstanten freisetzung besitzt, deren herstellung und verwendung.
Lee Kinetics of drug release from hydrogel matrices
DE3688873D1 (de) Biovertraegliche mikroporoese polymermaterialien und verfahren zu ihrer herstellung.
DK6380A (da) Polymer diffusionsmatrice fremgangsmaade til dens fremstilling og dens anvendelse
ATA326483A (de) Glaskuegelchen mit modifizierter oberflaeche, verfahren zu deren herstellung und verwendung derselben
DE3485618D1 (de) Zusammensetzung zur kontrollierten abgabe eines wirkstoffes und ihre herstellung.
ATE151298T1 (de) Behälter, der mit einer lösung eines aktiven prinzipes imprägnierbar ist, für eine iontophoretische vorrichtung zur transdermalen verabreichung von medikamenten, und verfahren zur herstellung eines solchen behälters
DE3860769D1 (de) Polymer-zusammensetzung, verfahren zu deren herstellung und deren anwendung.
ATE110415T1 (de) Verbessertes verfahren und apparat, um biologische substanzen in lebenden zellen einzuführen.
ATA784279A (de) Kieselsaeuregel, verfahren zu deren herstellung sowie deren verwendung
DK517782A (da) Fremgangsmaade til udbygning af lipidindholdet af en dyrket nitroorganisme samt carbonfrit kopipapir indeholdende et saaledes udbygget lipid
Lee et al. Fluoride ion diffusion from a glass–ionomer cement
ATE12731T1 (de) Polymere diffusionsmatrix und verfahren zu deren herstellung.
Albin Glucose-sensitive membranes for the controlled release of insulin
DE3860864D1 (de) Optisch aktive alpha-aminoaldehyde, verfahren zu ihrer herstellung und ihre verwendung zur stereoselektiven herstellung optisch aktiver beta-aminoalkohole.
DE58909724D1 (de) Verwendung einer Vorrichtung mit einem Wirkstoffreservoir für gesteuerte Wirkstoffabgabe
DE3862788D1 (de) Fluessige oxydationsmodifizierte ethylenische statistische copolymere, verfahren zur herstellung und deren verwendung.
ATE210431T1 (de) Polyurethan-hydrogel arzneistoffreservoirs zur verwendung in transdermalen arzneistoffverabreichungssystemen
Durkan et al. Water absorption of two different denture base resins reinforced with dental fiber systems
EP0055299A4 (de) ANTIBIOTIKUM Y-16482 alpha UND/ODER ANTIBIOTIKUM Y-16482 beta, VERFAHREN ZU DEREN HERSTELLUNG UND SIE ENTHALTENDE ARZNEIMITTELZUSAMMENSETZUNG.
JPS5211061A (en) Method to check quantity of liquid contained in an ampoule
Bortolami et al. Ultrastructural observations on the tapetum lucidum fibrosum
ES2073454T3 (es) Soporte para moleculas biologicamente activas o a su vez biologicamente activo, su procedimiento de preparacion y su aplicacion en biologia.
Mullon et al. A Mathematical Analysis of the U-Shaped Hybrid Artificial Pancreas-A Novel Insulin Release Rate Equation
Pywell et al. Drug release from polymeric, multi-perforated, laminated matrices

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee